GlobeNewsWire
31 May 2026, 23:30 UTC · 22w ago
Verdict
Headline takes no side. We score 6855 +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Updated clinical data for olverembatinib in CML-CP showed a 91.3% complete cytogenetic response (CCyR) and 60.9% major molecular response (MMR) rate at cycle 24.
More positive than 92% of claims this week
Ascentage Pharma is conducting three global registrational Phase III studies for olverembatinib, with two cleared by the FDA and EMA.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 85% of claims this week
The company has an exclusive option agreement with Takeda for the global rights to develop and commercialize olverembatinib outside of Greater China.
More positive than 76% of claims this week
Olverembatinib has a manageable safety profile with no new safety signals identified during long-term treatment.
More positive than 61% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company presented positive updated efficacy and safety data for olverembatinib at ASCO 2026.
More positive than 87% of ticker scores this week
The company presented positive updated efficacy and safety data for olverembatinib at ASCO 2026.
More positive than 57% of ticker scores this week
Innovent is jointly commercializing olverembatinib in China, benefiting from the positive clinical data.
More positive than 51% of ticker scores this week
Takeda holds an exclusive option agreement to license and commercialize olverembatinib globally outside of Greater China.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
9h ago
More positive than 37% of relationship scores this week
[mutual] Ascentage Pharma has signed an exclusive option agreement with Takeda for the licensing of olverembatinib.
—
No price for 6855 right now — the quote feed didn't answer.
6855 chart →
